Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as measured by functional magnetic resonance imaging (fMRI) in people with schizophrenia. Part 2 of the study will assess the safety and tolerability of multiple doses of AQW051 in people with schizophrenia.
A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Part 1: Assess BOLD response in key brain areas in schizophrenia patients during the performance of tasks as measured by (fMRI) in people with schizophrenia. [ Time Frame: 2 years (Part 1: 1 year) ]
Part 2: Assess safety and tolerability of multiple doses of AQW051 schizophrenia patients. [ Time Frame: Part 2: 8 months ]
Secondary Outcome Measures
Measure: To assess the effects of a single dose of AQW051 on performance of working and episodic memory tasks in people with schizophrenia. (Part 1) [ Time Frame: Time Frame: 2 years (Part 1: 1 year; Part 2: 8 months) ]
Measure: To determine the relationship of exposure to brain activation after a single dose of AQW051 in people with schizophrenia. (Part 1) [ Time Frame: 2 years (Part 1: 1 year; Part 2: 8 months) ]
Measure: To determine the dose-exposure response relationship of multiple doses of AQW051 in people with schizophrenia. (Part 2) [ Time Frame: 2 years (Part 1: 1 year; Part 2: 8 months) ]
Measure: To explore effects of multiple doses of AQW051 on measures of cognition in people with schizophrenia. (Part 2) [ Time Frame: 2 years (Part 1: 1 year; Part 2: 8 months) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM IV/DSM IV TR)
Subjects will be currently treated with the stable regimen of one or more of the following second generation antipsychotics: olanzapine, risperidone, paliperidone, quetiapine, ziprasidone, aripiprazole.
Subjects will meet the following symptom criteria:
Brief Psychiatric Rating Scale (BPRS) Hallucinatory Behavior or Unusual Thought Content item scores less than or equal to 5
BPRS Conceptual Disorganization item score less than or equal to 4
Simpson-Angus Scale (SAS) total score less than or equal to 6
Calgary Depression Scale (CDS) total score less than or equal to 10
Subjects will meet the following cognitive performance criteria:
Maximum performance level: Performance below 1.0 SD from perfect performance on the Hopkins Verbal Learning Test (HVLT) total (31 or less),
Minimum performance level: subject must be able to validly complete the fMRI cognitive paradigms
WTAR: 5th grade reading level assessment
Subjects must be symptomatically stable and not suffer from an acute exacerbation of their psychosis
Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study, through study completion. Pregnancy tests are required of all female subjects regardless of reported sterilization.
When performed at screening and practice visit, the result of this test must be received before the subject may be dosed.
Male subjects must be using two acceptable methods of contraception, (e.g., spermicidal gel plus condom) for the entire duration of the studyuntil the Study Completion visit.
Subject must have sufficiently stable overall health, as determined by the Investigator. The regular intake of concomitant drugs will be allowed, if the patient is on stable treatment for at least 3 months prior to study enrollment and the concomitant drug does not belong to the list of medication that are not allowed according to Appendix 3. If the patient takes more than one concomitant medication, it is at the Investigator's discretion to decide about the patient's eligibility, depending on the nature of the concomitant medications and the patient's overall health.
Current treatment with conventional antipsychotics (e.g. fluphenazine, haloperidol) or clozapine
Current treatment with an anticholinergic or other agent known to adversely interfere with the cholinergic system
Subjects with a DSM-IV diagnosis of substance abuse (other than nicotine) within the last month.
Subjects with a history of significant head injury/trauma, as defined by:
Loss of consciousness (LOC) for more than 1 hour
Recurring seizures resulting from the head injury
Clear cognitive sequelae of the injury
Cognitive rehabilitation following the injury
Subjects with a medical or neurological disorder or treatment for such disorder that could interfere with the study medication of the assessment of the subject
Use of certain concomitant medication
No grapefruit or grapefruit juice is to be consumed for 14 days prior to dosing until 7 days following the last dose.
Other protocol-defined inclusion/exclusion criteria may apply